Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will report Q4 and full-year 2025 financial results before the market opens on Tuesday, March 10, 2026. Management will host a live audio webcast at 8:00 a.m. ET to discuss results and business updates.

Webcast access and a replay will be available on the company's investor site, with the replay archived for approximately 90 days.

News Market Reaction – ESPR

-1.20%

1 alert

-1.20% News Effect

On the day this news was published, ESPR declined 1.20%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: March 10, 2026 Webcast time: 8:00 a.m. ET Replay availability: ≈2 hours after call +3 more

6 metrics

Earnings date March 10, 2026 Q4 and full year 2025 results scheduled before market open

Webcast time 8:00 a.m. ET Management webcast to discuss Q4 and full year 2025 results

Replay availability ≈2 hours after call Earnings webcast replay timing

Replay archive period ≈90 days Length of time webcast replay remains on company website

Marketed therapies 2 oral therapies Non-statin LDL-C therapies currently marketed by Esperion

Global approvals >40 countries Countries with approvals for Esperion’s LDL-C therapies

Market Reality Check

Price: $3.30 Vol: Volume 3,259,536 is at 0....

normal vol

$3.30 Last Close

Volume Volume 3,259,536 is at 0.85x the 20-day average of 3,813,505, indicating typical activity before this announcement. normal

Technical Price at $3.34 is trading above the $2.43 200-day moving average, reflecting a pre-news uptrend versus longer-term levels.

Peers on Argus

ESPR was down 4.02% pre-announcement while close peers showed mixed moves (e.g.,...

1 Up

ESPR was down 4.02% pre-announcement while close peers showed mixed moves (e.g., AQST up 1.92%, ORGO down 1.75%). Momentum scanners flagged only KMDA moving up, suggesting this looks stock-specific rather than a coordinated sector reaction.

Common Catalyst Within the peer group, at least one company (AQST) also issued an earnings date and conference call notice, pointing to an earnings-calendar theme rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	Conference participation	Neutral	+0.6%	Announcement of presentation at 2026 Citizens Life Sciences Conference.
Feb 17	Patent settlement	Positive	+3.5%	Settlement limiting generic entry for NEXLETOL and NEXLIZET until 2040.
Feb 11	Inducement grants	Neutral	+2.1%	Grant of 40,200 RSUs to new employees under inducement plan.
Jan 11	Business update	Positive	-8.5%	Preliminary 2025 results and long-term Vision 2040 growth strategy.
Jan 05	Conference participation	Neutral	+2.7%	Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference.

Pattern Detected

Recent ESPR headlines have usually seen modest positive price reactions, with one notable selloff on a strong business update and preliminary 2025 results.

Recent Company History

Over the last few months, ESPR has issued a series of operational and corporate updates. Conference participation announcements on Jan 5, 2026 and Feb 18, 2026 saw small positive moves. A patent litigation settlement on Feb 17, 2026 extending market protection to 2040 also coincided with a gain. Inducement equity grants in February produced a modest uptick. In contrast, a detailed business update with preliminary 2025 results and long-term "Vision 2040" strategy on Jan 11, 2026 was followed by an -8.51% reaction, showing the stock can sell off even after seemingly constructive news.

Market Pulse Summary

This announcement schedules Esperion’s fourth quarter and full year 2025 results for March 10, 2026,...

Analysis

This announcement schedules Esperion’s fourth quarter and full year 2025 results for March 10, 2026, with a webcast at 8:00 a.m. ET. In recent filings, the company reported growing revenue but continuing net losses and outlined 2026 operating expense expectations in an 8-K. Prior news on patent settlements and strategic updates also shaped the backdrop. Investors may focus on revenue growth, operating loss trends, cash levels, and expense guidance when those detailed results are released.

Key Terms

cardiometabolic, rare/orphan disease, low-density lipoprotein cholesterol (LDL-C), ACLY biology, +1 more

5 terms

cardiometabolic medical

"innovative cardiometabolic and rare/orphan disease therapies."

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

rare/orphan disease medical

"innovative cardiometabolic and rare/orphan disease therapies."

A rare or orphan disease is a serious medical condition that affects a very small portion of the population compared with common illnesses. These conditions often lack approved treatments because they are uncommon and costly to research. For investors, they matter because regulatory incentives, smaller clinical trial sizes, and high unmet need can make successful therapies commercially valuable — similar to serving a tiny market that will pay a premium for a solution.

low-density lipoprotein cholesterol (LDL-C) medical

"maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk"

Low-density lipoprotein cholesterol (LDL-C) is the portion of blood cholesterol carried by particles that deliver cholesterol to arteries; think of LDL-C as delivery trucks that can leave sticky deposits in vessel walls. Investors care because high LDL-C levels drive demand for tests, medications, medical devices and preventive care, influence clinical trial outcomes and regulatory decisions, and help determine future healthcare spending and revenue for companies in the cardiovascular sector.

ACLY biology medical

"The Company leverages deep domain expertise in ACLY biology to develop"

ACLY biology concerns the role of the enzyme ATP citrate lyase (ACLY) in converting cell fuel into acetyl units used to build fats and modify proteins, essentially acting like a factory machine that turns raw energy into construction materials for cells. Investors care because ACLY is a common drug target for conditions such as metabolic disease, fatty liver and some cancers; changes in ACLY-related research or therapies can affect the value of companies developing treatments or diagnostics.

renal diseases medical

"including treatments for Primary Sclerosing Cholangitis and renal diseases."

Renal diseases are conditions that damage the kidneys’ ability to filter waste, balance fluids, and regulate blood pressure, ranging from mild impairment to kidney failure that may require dialysis or transplant. For investors, these diseases drive demand for diagnostics, medicines, medical devices, and long-term care—think of kidneys as a home’s plumbing: when they fail, products and treatments to repair or replace that system become commercially important and can affect company revenues and regulatory scrutiny.

AI-generated analysis. Not financial advice.

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) release its Q4 and full-year 2025 results?

Esperion will release Q4 and full-year 2025 results before market open on March 10, 2026. According to the company, management will discuss results during an 8:00 a.m. ET webcast the same day.

How can investors access the Esperion (ESPR) March 10, 2026 earnings webcast?

Investors can access a live audio webcast via the company's investor website at 8:00 a.m. ET on March 10, 2026. According to the company, a replay will be available about two hours after the call.

Will Esperion (ESPR) provide a replay of the March 10, 2026 earnings call and for how long?

Yes, a replay will be available approximately two hours after the call and archived for about 90 days. According to the company, the replay is hosted on its investor and media website.

What topics will Esperion (ESPR) management discuss during the March 10, 2026 webcast?

Management will discuss the fourth quarter and full-year 2025 financial results and provide business updates. According to the company, the webcast will cover commercial progress and program updates.

Who should I contact for investor or media questions about Esperion (ESPR)?

For investor inquiries contact Alina Venezia; for media contact Tiffany Aldrich, both via company-provided emails and phone numbers. According to the company, contact details are listed on its website.